Compare XRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | ENTA |
|---|---|---|
| Founded | 1906 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.6M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | XRX | ENTA |
|---|---|---|
| Price | $2.78 | $14.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.50 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 3.4M | 298.8K |
| Earning Date | 01-27-2026 | 11-17-2025 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,607,000,000.00 | $65,324,000.00 |
| Revenue This Year | $12.39 | $0.99 |
| Revenue Next Year | $8.31 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.67 | N/A |
| 52 Week Low | $2.32 | $4.09 |
| 52 Week High | $9.91 | $15.34 |
| Indicator | XRX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 68.50 |
| Support Level | $2.51 | $13.99 |
| Resistance Level | $2.74 | $14.79 |
| Average True Range (ATR) | 0.14 | 0.73 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 54.74 | 88.35 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.